J Clin Oncol. 2024 Jun 24:JCO2400544. doi: 10.1200/JCO.24.00544. Online ahead of print.
NO ABSTRACT
PMID:38913961 | DOI:10.1200/JCO.24.00544
Recent Content
- A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
- Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma
- Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
- Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
- Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
- Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
- Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
- Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
- Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
- Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma